Eli Lilly (NYSE: LLY) is rapidly advancing its strategy to expand the availability of its weight loss and diabetes medications to key international markets. According to remarks made by the company’s CFO, Lucas Montarce, at the Leerink 2025 Global Healthcare Conference, Lilly is preparing to enter several major emerging markets by the end of 2025.
Montarce emphasized that Brazil, Mexico, and other large, high-potential markets are central to Lilly’s growth plans. “We’re targeting emerging market countries that are poised to drive substantial growth, particularly in the latter half of this year and into 2026, including China, India, Brazil, and Mexico,” he explained, referring specifically to the company’s incretin-based drugs, which include GLP-1 and GLP-1/GIP receptor agonists.
Lilly has already made significant strides in its global expansion, launching new drugs in over 30 countries throughout 2024. The company’s aggressive approach signals a major push to capitalize on international demand for treatments addressing weight loss and diabetes.
Related Topics:
Does Medicare Cover Weight Loss Injections
Are Lipotropic Injections Dangerous
How I Overcame My Fear of Needles to Start Ozempic for Weight Loss
